N
Neumora Therapeutics Inc
NASDAQ:NMRA
Neumora Therapeutics Inc
NASDAQ:NMRA
Price:
2.06
USD
0.98%
Market Closed
Market Cap:
$339.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Neumora Therapeutics Inc
NASDAQ:NMRA
|
US |
|
B
|
Bangkok Chain Hospital PCL
SET:BCH
|
TH |
|
Red Sea International Company SJSC
SAU:4230
|
SA |
|
Zhejiang Shuanghuan Driveline Co Ltd
SZSE:002472
|
CN |
|
C
|
Cowell e Holdings Inc
HKEX:1415
|
CN |
|
S
|
Sunic System Co Ltd
KOSDAQ:171090
|
KR |
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
US |
|
Sanhe Tongfei Refrigeration Co Ltd
SZSE:300990
|
CN |
|
Y
|
Yijia Group Corp
OTC:YJGJ
|
HK |
|
S
|
Shanghai Xinpeng Industry Co Ltd
SZSE:002328
|
CN |
|
ZG Group
HKEX:6676
|
CN |
|
A
|
Abhinav Leasing & Finance Ltd
BSE:538952
|
IN |
|
Classic Minerals Ltd
ASX:CLZ
|
AU |
Income Statement
Earnings Waterfall
Neumora Therapeutics Inc
Neumora Therapeutics Inc
Income Statement
Neumora Therapeutics Inc
Neumora Therapeutics Inc
Currency: USD
| Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(69)
|
(80)
|
(95)
|
(109)
|
(123)
|
(193)
|
(204)
|
(261)
|
(188)
|
(273)
|
(295)
|
(315)
|
(263)
|
(274)
|
(265)
|
(241)
|
(236)
|
|
| Selling, General & Administrative |
(21)
|
(25)
|
(29)
|
(30)
|
(31)
|
(49)
|
(50)
|
(65)
|
(45)
|
(50)
|
(56)
|
(57)
|
(63)
|
(67)
|
(67)
|
(63)
|
(60)
|
|
| Research & Development |
(48)
|
(56)
|
(66)
|
(79)
|
(92)
|
(145)
|
(154)
|
(196)
|
(143)
|
(159)
|
(175)
|
(194)
|
(201)
|
(207)
|
(197)
|
(177)
|
(176)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(64)
|
(64)
|
(64)
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(69)
N/A
|
(80)
-16%
|
(95)
-18%
|
(109)
-15%
|
(123)
-12%
|
(193)
-57%
|
(204)
-6%
|
(261)
-28%
|
(188)
+28%
|
(273)
-45%
|
(295)
-8%
|
(315)
-7%
|
(263)
+16%
|
(274)
-4%
|
(265)
+4%
|
(241)
+9%
|
(236)
+2%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
1
|
5
|
9
|
12
|
16
|
17
|
19
|
21
|
21
|
20
|
17
|
13
|
10
|
5
|
|
| Non-Reccuring Items |
(161)
|
(157)
|
(170)
|
(170)
|
(13)
|
(13)
|
(13)
|
(13)
|
(64)
|
0
|
0
|
0
|
0
|
0
|
0
|
(5)
|
(5)
|
|
| Total Other Income |
(0)
|
0
|
(0)
|
(0)
|
0
|
1
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(1)
|
|
| Pre-Tax Income |
(230)
N/A
|
(237)
-3%
|
(265)
-12%
|
(278)
-5%
|
(131)
+53%
|
(197)
-50%
|
(205)
-4%
|
(258)
-26%
|
(236)
+9%
|
(254)
-8%
|
(274)
-8%
|
(293)
-7%
|
(244)
+17%
|
(258)
-6%
|
(252)
+2%
|
(236)
+6%
|
(237)
0%
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(230)
|
(237)
|
(265)
|
(278)
|
(131)
|
(197)
|
(205)
|
(258)
|
(236)
|
(254)
|
(274)
|
(294)
|
(244)
|
(258)
|
(252)
|
(236)
|
(237)
|
|
| Net Income (Common) |
(230)
N/A
|
(237)
-3%
|
(265)
-12%
|
(278)
-5%
|
(131)
+53%
|
(197)
-50%
|
(205)
-4%
|
(258)
-26%
|
(236)
+9%
|
(254)
-8%
|
(274)
-8%
|
(294)
-7%
|
(244)
+17%
|
(258)
-6%
|
(252)
+2%
|
(236)
+6%
|
(237)
0%
|
|
| EPS (Diluted) |
-1.51
N/A
|
-1.56
-3%
|
-1.74
-12%
|
-1.83
-5%
|
-0.86
+53%
|
-1.29
-50%
|
-1.34
-4%
|
-1.69
-26%
|
-1.49
+12%
|
-1.6
-7%
|
-1.72
-7%
|
-1.84
-7%
|
-1.53
+17%
|
-1.61
-5%
|
-1.57
+2%
|
-1.46
+7%
|
-1.45
+1%
|
|
Switch to:
Switch to:
See Also
Discover More
